ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper

/PRNewswire/ -- ZyVersa Therapeutics, Inc., (ZyVersa) a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of...

Related Keywords

Miami ,Florida ,United States ,Rivero Vaccari ,Robertw Keane ,Purpose Acquisition Company ,Prnewswire Zyversa Therapeutics Inc ,Department Of Neurological Surgery ,Drug Administration ,Zyversa Therapeutics Inc ,Nasdaq ,University Of Miami Miller School Medicine ,Faculty Member Of The Center ,Larkspur Health Acquisition Corp ,Translational Research ,Versa Therapeutics ,Larkspur Health Acquisition ,Miami Miller School ,Juan Pablo De Rivero ,Neurological Surgery ,Juan Pablo De Rivero Vaccari ,Associate Professor ,Miami Project ,Cure Paralysis ,Distinguished Faculty Member ,Cognitive Neuroscience ,Click Here ,Zyversa Therapeutics ,Alport Syndrome ,Diabetic Kidney ,Special Purpose Acquisition Company ,Business Combination Agreement ,Merger Agreement ,Annual Report ,Nc Larkspur Health Acquisition Corp ,